CURIS INC

CRISSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1108205

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$10.0M	$10.2M	$10.6M	$10.0M	$1.8M
Research and Development Expense	—	—	—	—	—
Operating Income (Loss)	-$48.3M	-$53.0M	-$42.1M	-$24.4M	-$5.6M
Interest Expense	—	—	—	$791.0K	$791.0K
Nonoperating Income (Expense)	$919.0K	-$3.7M	-$3.4M	-$7.8M	-$7.8M
Net Income (Loss) Attributable to Parent	-$47.4M	-$56.7M	-$45.4M	-$32.1M	-$9.9M
Earnings Per Share, Basic	-$8.96	-$12.14	$0.50	-$0.97

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$77.3M	$108.8M	$162.3M	$204.4M	$35.1M
Assets, Current	$60.9M	$92.1M	$122.4M	$172.8M	$25.0M
Cash and Cash Equivalents, at Carrying Value	$26.7M	$19.7M	$40.0M	$129.6M	$15.4M
Accounts Receivable, after Allowance for Credit Loss, Current	$2.8M	$3.0M	$3.2M	$3.0M	$3.2M
Liabilities	$57.6M	$62.3M	$71.6M	$73.7M	$69.0M
Liabilities, Current	$22.0M	$10.0M	$13.4M	$10.1M	$6.5M
Long-term Debt	—	—	$900.0K	$900.0K

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$38.4M	-$54.3M	-$37.6M	-$26.2M	-$26.2M
Net Cash Provided by (Used in) Investing Activities	$37.8M	$33.0M	-$47.9M	-$4.5M	-$4.5M
Net Cash Provided by (Used in) Financing Activities	$7.6M	$867.0K	-$4.2M	$23.3M	$23.3M
Payments to Acquire Property, Plant, and Equipment	—	$416.0K	$0.00	$41.0K	$41.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)